Corrigendum to 'Coronavirus disease 2019 in patients with neuroendocrine neoplasms: Preliminary results of the INTENSIVE study' [European Journal of Cancer 154 (2021) 246-252]
1 Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology (IEO) IRCCS, Milan, Italy. Electronic address: nicola.fazio@ieo.it.
2 Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology (IEO) IRCCS, Milan, Italy; Molecular Medicine Program, University of Pavia, Pavia, Italy.
3 Division of Medical Oncology Mayo Clinic, Rochester, MN, USA.
4 Medical Oncology Department, Hospital Universitario Doce de Octubre, Imas12, UCM, Madrid, Spain.
5 Department of Internal Medicine, Sector Endocrinology, Rotterdam, the Netherlands.
6 Vall Hebron University Hospital and Vall Hebron Institute of Oncology (VHIO), Barcelona, Spain.
7 Department of Hematology and Oncology Mayo Clinic, Phoenix, AZ, USA.
8 Hematology-Oncology Unit, Fourth Department of Internal Medicine, Attikon Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
9 1st Department of Propaedeutic Internal Medicine, Endocrine Unit, National and Kapodistrian, University of Athens, Athens, 11527, Greece.
10 Oncology Unit and Centro Documentazione Osteonecrosi, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
11 Neuroendocrine Tumors Unit, ENETS Center of Excellence, Department of Endocrinology and Metabolism Service, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
12 Data Management-Clinical Trial Office. Scientific Direction. European Institute of Oncology (IEO) IRCCS, Milan, Italy.
13 Department of Statistics and Quantitative Methods, University of Milan-Bicocca, Milan, Italy.
14 Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology (IEO) IRCCS, Milan, Italy.